Page last updated: 2024-09-04

ampelopsin and Leukemia, Promyelocytic, Acute

ampelopsin has been researched along with Leukemia, Promyelocytic, Acute in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Fu, HL; He, MH; Liang, XX; Lin, JC; Shi, F; Shu, G; Yin, L; Yuan, ZX; Zhang, Q; Zhao, L	1

Other Studies

1 other study(ies) available for ampelopsin and Leukemia, Promyelocytic, Acute

Article	Year
Dihydromyricetin sensitizes human acute myeloid leukemia cells to retinoic acid-induced myeloid differentiation by activating STAT1. Biochemical and biophysical research communications, 2018, 01-08, Volume: 495, Issue:2 Topics: Antineoplastic Agents; Cell Differentiation; Cell Line, Tumor; Drug Synergism; Flavonols; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; MAP Kinase Signaling System; Oncogene Proteins, Fusion; Proteolysis; Signal Transduction; STAT1 Transcription Factor; Tretinoin	2018

Article

Year

Dihydromyricetin sensitizes human acute myeloid leukemia cells to retinoic acid-induced myeloid differentiation by activating STAT1.

Biochemical and biophysical research communications, 2018, 01-08, Volume: 495, Issue:2

Topics: Antineoplastic Agents; Cell Differentiation; Cell Line, Tumor; Drug Synergism; Flavonols; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; MAP Kinase Signaling System; Oncogene Proteins, Fusion; Proteolysis; Signal Transduction; STAT1 Transcription Factor; Tretinoin

2018